Expertise in
11
conditions

Dr. Namita Sood

Intensive Care Medicine
University Of California Davis
2825 J St Ste 400, 
Sacramento, CA 
Offers Telehealth
Expertise in
11
conditions
University Of California Davis
2825 J St Ste 400, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Namita Sood is an Intensive Care Medicine provider in Sacramento, California. Dr. Sood is highly rated in 11 conditions, according to our data. Her top areas of expertise are Pulmonary Hypertension, Acute Interstitial Pneumonia, Interstitial Lung Disease, and Pulmonary Veno-Occlusive Disease.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Licenses
Critical Care Medicine in OH
Hospital Affiliations
Mercy Medical Center Redding
Marshall Medical Center
Sutter Medical Center, Sacramento
Mercy Medical Center Of Mt Shasta
University Of California Davis Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
California Health And Wellness
  • MANAGED MEDICAID PLAN
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 19 Less Insurance Carriers -

Locations

University of California Davis
2825 J St Ste 400, Sacramento, CA 95816
Call: 916-734-0779

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Rodatristat Ethyl
Study Phase: Phase 2
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: April 19, 2023
Intervention Type: Drug, Other
Study Drug: Sotatercept
Study Phase: Phase 2
A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-ranging Study Evaluating LTI-01 (Single-chain Urokinase Plasminogen Activator, scuPA) in Patients With Infected, Non-draining Pleural Effusions
A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-ranging Study Evaluating LTI-01 (Single-chain Urokinase Plasminogen Activator, scuPA) in Patients With Infected, Non-draining Pleural Effusions
Enrollment Status: Completed
Publish Date: March 30, 2023
Intervention Type: Drug
Study Drug: LTI-01
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
The Expression and Significance of miRNA Profile and Markers of Inflammation in Patients With Pulmonary Arterial Hypertension
The Expression and Significance of miRNA Profile and Markers of Inflammation in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: November 02, 2021
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2a, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Patients With Pulmonary Arterial Hypertension
A Phase 2a, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: March 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 15 Less Clinical Trials

27 Total Publications

Baseline and Change in Peripheral Blood Transcriptome Enhance Outcome Prediction in Fibrotic Hypersensitivity Pneumonitis: A Prospective Multicenter Cohort Study.
Baseline and Change in Peripheral Blood Transcriptome Enhance Outcome Prediction in Fibrotic Hypersensitivity Pneumonitis: A Prospective Multicenter Cohort Study.
Journal: medRxiv : the preprint server for health sciences
Published: November 26, 2025
View All 27 Publications
Similar Doctors
Expertise in
17
conditions
Dr. Brian Morrissey
Intensive Care Medicine
Expertise in
17
conditions
Dr. Brian Morrissey
Intensive Care Medicine

University Of California Davis

2825 J St Ste 400, 
Sacramento, CA 
 (0.2 miles away)
916-734-0779
Languages Spoken:
English
See accepted insurances

Brian Morrissey is an Intensive Care Medicine provider in Sacramento, California. Dr. Morrissey is highly rated in 17 conditions, according to our data. His top areas of expertise are Cystic Fibrosis, Bronchiectasis, Acute Interstitial Pneumonia, Lung Metastases, and Endoscopy.

Expertise in
15
conditions
Dr. Samuel Louie
Intensive Care Medicine
Expertise in
15
conditions
Dr. Samuel Louie
Intensive Care Medicine

University Of California Davis

2825 J St Ste 400, 
Sacramento, CA 
 (0.2 miles away)
916-734-0779
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Samuel Louie is an Intensive Care Medicine provider in Sacramento, California. Dr. Louie is highly rated in 15 conditions, according to our data. His top areas of expertise are Eosinophilic Asthma, Chronic Eosinophilic Pneumonia, Eosinophilic Pneumonia, and Simple Pulmonary Eosinophilia.

Mark Avdalovic
Expertise in
10
conditions
Dr. Mark Avdalovic
Intensive Care Medicine
Expertise in
10
conditions
Dr. Mark Avdalovic
Intensive Care Medicine

University Of California Davis

2825 J St Ste 400, 
Sacramento, CA 
 (0.2 miles away)
916-734-0779
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Avdalovic is an Intensive Care Medicine provider in Sacramento, California. Dr. Avdalovic is highly rated in 10 conditions, according to our data. His top areas of expertise are Pulmonary Veno-Occlusive Disease, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sood's expertise for a condition
ConditionClose
  • Elite
  • Pulmonary Hypertension
    Dr. Sood is
    Elite
    . Learn about Pulmonary Hypertension.
    See more Pulmonary Hypertension experts
  • Distinguished
  • Acute Interstitial Pneumonia
    Dr. Sood is
    Distinguished
    . Learn about Acute Interstitial Pneumonia.
    See more Acute Interstitial Pneumonia experts
  • Hypersensitivity Pneumonitis
    Dr. Sood is
    Distinguished
    . Learn about Hypersensitivity Pneumonitis.
    See more Hypersensitivity Pneumonitis experts
  • Interstitial Lung Disease
    Dr. Sood is
    Distinguished
    . Learn about Interstitial Lung Disease.
    See more Interstitial Lung Disease experts
  • Lung Metastases
    Dr. Sood is
    Distinguished
    . Learn about Lung Metastases.
    See more Lung Metastases experts
  • Pneumonia
    Dr. Sood is
    Distinguished
    . Learn about Pneumonia.
    See more Pneumonia experts
  • Pulmonary Veno-Occlusive Disease
    Dr. Sood is
    Distinguished
    . Learn about Pulmonary Veno-Occlusive Disease.
    See more Pulmonary Veno-Occlusive Disease experts
  • Advanced
  • Exogenous Lipoid Pneumonia
    Dr. Sood is
    Advanced
    . Learn about Exogenous Lipoid Pneumonia.
    See more Exogenous Lipoid Pneumonia experts
  • Idiopathic Pulmonary Fibrosis
    Dr. Sood is
    Advanced
    . Learn about Idiopathic Pulmonary Fibrosis.
    See more Idiopathic Pulmonary Fibrosis experts
  • Pulmonary Fibrosis
    Dr. Sood is
    Advanced
    . Learn about Pulmonary Fibrosis.
    See more Pulmonary Fibrosis experts
  • Systemic Sclerosis (SSc)
    Dr. Sood is
    Advanced
    . Learn about Systemic Sclerosis (SSc).
    See more Systemic Sclerosis (SSc) experts
  • Experienced
  • Bronchiectasis
    Dr. Sood is
    Experienced
    . Learn about Bronchiectasis.
    See more Bronchiectasis experts
  • Bronchogenic Cyst
    Dr. Sood is
    Experienced
    . Learn about Bronchogenic Cyst.
    See more Bronchogenic Cyst experts
  • Bullae
    Dr. Sood is
    Experienced
    . Learn about Bullae.
    See more Bullae experts
  • Cerebral Hypoxia
    Dr. Sood is
    Experienced
    . Learn about Cerebral Hypoxia.
    See more Cerebral Hypoxia experts
  • Cholesterol Pneumonia
    Dr. Sood is
    Experienced
    . Learn about Cholesterol Pneumonia.
    See more Cholesterol Pneumonia experts
  • Chronic Obstructive Pulmonary Disease (COPD)
    Dr. Sood is
    Experienced
    . Learn about Chronic Obstructive Pulmonary Disease (COPD).
    See more Chronic Obstructive Pulmonary Disease (COPD) experts
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
  1. Homepage
  2. Dr. Namita Sood
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.